KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Total Liabilities: 2010-2025

Historic Total Liabilities for TherapeuticsMD (TXMD) over the last 10 years, with Sep 2025 value amounting to $11.2 million.

  • TherapeuticsMD's Total Liabilities fell 9.88% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.2 million, marking a year-over-year decrease of 9.88%. This contributed to the annual value of $11.5 million for FY2024, which is 18.33% down from last year.
  • As of Q3 2025, TherapeuticsMD's Total Liabilities stood at $11.2 million, which was up 0.13% from $11.2 million recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Total Liabilities ranged from a high of $274.0 million in Q1 2022 and a low of $11.2 million during Q2 2025.
  • For the 3-year period, TherapeuticsMD's Total Liabilities averaged around $15.5 million, with its median value being $12.5 million (2024).
  • Its Total Liabilities has fluctuated over the past 5 years, first rose by 10.12% in 2022, then tumbled by 89.93% in 2023.
  • Over the past 5 years, TherapeuticsMD's Total Liabilities (Quarterly) stood at $263.1 million in 2021, then plummeted by 78.98% to $55.3 million in 2022, then slumped by 74.65% to $14.0 million in 2023, then fell by 18.33% to $11.5 million in 2024, then declined by 9.88% to $11.2 million in 2025.
  • Its Total Liabilities was $11.2 million in Q3 2025, compared to $11.2 million in Q2 2025 and $11.5 million in Q1 2025.